全文获取类型
收费全文 | 477篇 |
免费 | 69篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 20篇 |
妇产科学 | 13篇 |
基础医学 | 199篇 |
临床医学 | 19篇 |
内科学 | 68篇 |
皮肤病学 | 8篇 |
神经病学 | 7篇 |
特种医学 | 1篇 |
外科学 | 33篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 11篇 |
眼科学 | 2篇 |
药学 | 7篇 |
肿瘤学 | 154篇 |
出版年
2024年 | 1篇 |
2023年 | 32篇 |
2022年 | 12篇 |
2021年 | 34篇 |
2020年 | 29篇 |
2019年 | 28篇 |
2018年 | 28篇 |
2017年 | 19篇 |
2016年 | 21篇 |
2015年 | 26篇 |
2014年 | 23篇 |
2013年 | 31篇 |
2012年 | 20篇 |
2011年 | 16篇 |
2010年 | 19篇 |
2009年 | 12篇 |
2008年 | 27篇 |
2007年 | 20篇 |
2006年 | 18篇 |
2005年 | 21篇 |
2004年 | 21篇 |
2003年 | 18篇 |
2002年 | 20篇 |
2001年 | 12篇 |
2000年 | 11篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 9篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1988年 | 1篇 |
排序方式: 共有551条查询结果,搜索用时 15 毫秒
1.
2.
Transformation of a Drosophila virilis white mutant host strain was attempted using a hobo vector containing the D. melanogaster mini-white+ cassette (H[w+, hawN]) and an unmodified or heat shock regulated hobo transposase helper. Two transformant lines were recovered with the unmodified helper (HFL1), one containing only the white+ marked vector, and a sibling line containing the vector as well as an HFL1 helper integration. An approximate total transformation frequency of 1% is deduced. A high frequency of wing and eye morphology mutants were also observed, suggesting that hobo may have mobilized a related element in D. virilis. The data reaffirms a relatively low transformation vector activity for the hobo transposon in D. virilis; however, nearly full interspecific expression of the white+ marker supports its possible function in other species as well. 相似文献
3.
A novel STK11 germline mutation in two siblings with Peutz-Jeghers syndrome complicated by primary gastric cancer 总被引:1,自引:0,他引:1
Shinmura K Goto M Tao H Shimizu S Otsuki Y Kobayashi H Ushida S Suzuki K Tsuneyoshi T Sugimura H 《Clinical genetics》2005,67(1):81-86
Patients with Peutz-Jeghers syndrome (PJS) are known to be at risk of gastric cancer (GC), and the STK11 gene is a susceptibility gene for PJS. However, as no cases of PJS with GC in which a STK11 germline mutation has been identified have ever been reported and other susceptibility genes have also been suggested to be involved in PJS, the relation between STK11 germline mutations and GC in PJS is still unknown. In this study, we used sequencing analysis to investigate the STK11, CDH1, and TP53 loci for a germline mutation in two siblings with PJS with primary GC. A novel type of the STK11 germline mutation, c.890delG, encoding a truncated protein (p.Arg297fsX38) was identified, but no germline mutations of the CDH1 and TP53 genes were detected. No inactivation of the wild-type allele by somatic mutation or chromosomal deletion or hypermethylation at the 5'-CpG site of STK11 was detected in the GC. This is the first report of a STK11 germline mutation in a PJS patient with GC and should contribute to establishing correlations between the STK11 germline mutations and GC in PJS patients. 相似文献
4.
Launonen V 《Human mutation》2005,26(4):291-297
The human LKB gene (official HUGO symbol, STK11) encodes a serine/threonine protein kinase that is defective in patients with Peutz-Jeghers syndrome (PJS). PJS is an autosomal dominantly inherited syndrome characterized by hamartomatous polyposis of the gastrointestinal tract and mucocutaneous pigmentation. To date, 145 different germline LKB1 mutations have been reported. The majority of the mutations lead to a truncated protein product. One mutational hotspot has been observed. A 1-bp deletion and a 1-bp insertion at the mononucleotide repeat (C6 repeat, c.837-c.842) between the codons 279-281 have been found in six and seven unrelated PJS families, respectively. However, these mutations account only for approximately 7% of all mutations identified in the PJS families (13/193). A review of the literature provides a total of 40 different somatic LKB1 mutations in 41 sporadic tumors and seven cancer cell lines. Mutations occur particularly in lung and colorectal cancer. Most of the somatic LKB1 mutations result in truncation of the protein. A mutational hotspot seems to be a C6 repeat accounting for 12.5% of all somatic mutations (6/48). These results are concordant with the germline mutation spectrum. However, the proportion of the missense mutations seems to be higher among the somatic mutations (45%) than among the germline mutations (21%), and only seven of the mutations are exactly the same in both of the mutation types. 相似文献
5.
Hippo pathway and its related genes are required for growth control in various somatic tissues. The mutations of Hippo pathway components lead to tissue overgrowth cell-autonomously. Surprisingly, when we generated germline mutant clones of Hippo-network genes such as fat, expanded, hippo, salvador, and warts, we did not observe any overgrowth of these mutant cells. Consistently, overexpression of the progrowth gene yorkie, which is normally inhibited by Hippo signaling, did not lead to germline overgrowth either. In contrast to previous studies in epithelial tissues, these tumor suppressor genes are dispensable in germline cells for their proliferation control. Furthermore, we demonstrate that expanded functions nonautonomously to regulate spermatogonial proliferation. It appears that expanded acts from the somatic support cells surrounding the germline to restrict spermatogonial amplification. 相似文献
6.
Keisuke Yoshihama Hideki Mutai Mariko Sekimizu Fumihiro Ito Shin Saito Shintaro Nakamura Takuya Mikoshiba Ryoto Nagai Akiko Takebayashi Fuyuki Miya Kenjiro Kosaki Hiroyuki Ozawa Tatsuo Matsunaga 《Clinical genetics》2023,103(4):466-471
Carotid body tumor (CBT) is classified as a paraganglioma (PGL). Here, we report the genetic background, protein expression pattern, and clinical findings of 30 Japanese CBT cases. Germline pathogenic or likely pathogenic (P/LP) variants of genes encoding succinate dehydrogenase subunits (SDHs) were detected in 15 of 30 cases (50%). The SDHB variants were the most frequently detected, followed by SDHA and SDHD variants. One case with SDHAF2 variant was bilateral CBT, and other two multiple PGL cases were not detected P/LP variants. The three cases with germline variants that could be tested did not have somatic P/LP variants of the same genes. Immunohistochemical analysis showed negative SDHB signals in CBT tissues in five cases with germline P/LP variants of SDHB, SDHD, or SDHA. In addition, SDHB signals in CBT tissues were negative in four of nine cases without germline P/LP variants of SDHs. These findings suggest the involvement of unidentified molecular mechanisms affecting SDHs. 相似文献
7.
8.
《Expert opinion on biological therapy》2013,13(7):1061-1075
Importance of the field: Immunotherapy holds great potential for disseminated cancer, and cancer–germline (CG) antigens are among the most promising tumor targets. They are widely expressed in different cancer types and are essentially tumor-specific, since their expression in normal tissues is largely restricted to immune-privileged sites. Although the therapeutic potential of these antigens may be compromised by their highly heterogeneous expression in many tumors and low frequency in some cancers, recent developments suggest that tumor-cell-selective enhancement of CG antigen gene expression can be achieved using epigenetic modifiers.Areas covered in this review: We provide an overview of the potential of CG antigens as targets for cancer immunotherapy, including advantages and disadvantages. We also discuss the current state of development of CG antigen vaccines, and the potential synergistic effect of combining CG antigen immunotherapeutic strategies with epigenetic modifiers.What the reader will gain: The reader will gain an overview of the past, present and future role of CG antigens in cancer immunotherapy.Take home message: Chemoimmunotherapy using epigenetic drugs and CG antigen vaccines may be a useful approach for treating cancer. 相似文献
9.
BackgroundApproximately 5–10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes. The poly-ADP ribose polymerase (PARP)-inhibitors olaparib and talazoparib have been granted marketing authorization by both FDA and EMA for adults with BRCA1/2 germline mutations and HER2-negative (HER2-) advanced BC based on the results from the phase III OlympiAd and EMBRACA trials.MethodsThe panel of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Breast Cancer addressed two critical clinical questions, adopting the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach and the Evidence to Decision framework (EtD), to develop recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related triple-negative (clinical question 1) and hormone receptor-positive (HR+)/HER2- (clinical question 2) advanced BC.ResultsTwo studies were eligible (OlympiAd and EMBRACA). For both clinical questions, the Panel judged the benefit/harm balance probably in favor of the intervention, given the favorable impact in terms of PFS, ORR, and QoL at an acceptable cost in terms of toxicity; the overall certainty of the evidence was low. The panel's final recommendations were conditional in favor of PARP-inhibitors over single-agent chemotherapy in both HR+/HER2-and triple-negative BC. Finally, the Panel identified and discussed areas of uncertainty calling for further exploration.ConclusionsThe Panel of AIOM BC Clinical Practice Guideline provided clinical recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related HER2-advanced BC by adopting the GRADE methodology. 相似文献
10.
Contrasting mechanisms of de novo copy number mutagenesis suggest the existence of different classes of environmental copy number mutagens 下载免费PDF全文
While gene copy number variations (CNVs) are abundant in the human genome, and often are associated with disease consequences, the mutagenic pathways and environmental exposures that cause these large structural mutations are understudied relative to conventional nucleotide substitutions in DNA. The members of the environmental mutagenesis community are currently seeking to remedy this deficiency, and there is a renewed interest in the development of mutagenicity assays to identify and characterize compounds that may induce de novo CNVs in humans. To achieve this goal, it is critically important to acknowledge that CNVs exist in two very distinct classes: nonrecurrent and recurrent CNVs. The goal of this commentary is to emphasize the deep contrasts that exist between the proposed pathways that lead to these two mutation classes. Nonrecurrent de novo CNVs originate primarily in mitotic cells through replication‐dependent DNA repair pathways that involve microhomologies (<10 bp), and are detected at higher frequency in children of older fathers. In contrast, recurrent de novo CNVs are most often formed in meiotic cells through homologous recombination between nonallelic large low‐copy repeats (>10,000 bp), without an associated paternal age effect. Given the biological differences between the two CNV classes, it is our belief that nonrecurrent and recurrent CN mutagens will probably differ substantially in their modes of action. Therefore, each CNV class may require their own uniquely designed assays, so that we as a field may succeed in uncovering the broadest possible spectrum of environmental CN mutagens. Environ. Mol. Mutagen. 57:3–9, 2016. © 2015 Wiley Periodicals, Inc. 相似文献